Marshall Wace, LLP Oncorus, Inc. Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021
SELL
$13.3 - $17.3 $717,574 - $933,386
-53,953 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$11.89 - $35.55 $641,501 - $1.92 Million
53,953 New
53,953 $751,000

About Oncorus, Inc.

ONCR Quotes by TradingView
  • Ticker ONCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,973,100
  • Description
  • Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...
More about ONCR
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email